What is EU-GMP and Why Does It Matter?
EU Good Manufacturing Practice (EU-GMP) is the gold standard for pharmaceutical manufacturing in Europe. It is a regulatory framework mandated by the European Medicines Agency (EMA) that defines rigorous standards for production processes, quality control, documentation, personnel, facilities and distribution. Every batch of Cannamedical Britannia product is manufactured in compliance with EU-GMP — the same standard applied to conventional pharmaceuticals.
In a market where product quality can vary significantly, EU-GMP certification provides patients, clinicians and pharmacies with an assurance that what is on the label is what is in the product: correct cannabinoid content, absence of pesticides, heavy metals, microbiological contaminants and residual solvents, all verified analytically for every batch.
Our Quality Chain: Cultivator to Patient
Cannamedical Pharma GmbH has established partnerships with over 30 EU-GMP certified cultivators across Europe and beyond. Our quality management process covers every step of the supply chain:
- Cultivation: Controlled environment growing under EU-GMP conditions. Genetics documented and consistent across batches. Pesticide-free protocols with residue testing.
- Harvesting and Drying: Standardised processes to preserve cannabinoid and terpene profiles. Temperature and humidity controlled throughout.
- Processing and Manufacturing: EU-GMP certified manufacturing facilities. Batch-level records maintained for full traceability.
- Quality Control: Independent third-party laboratory testing for every batch. Parameters include: THC, CBD, CBG and full cannabinoid panel; terpene profile; water activity; microbial contamination; mycotoxins; heavy metals; pesticide residues; residual solvents.
- Distribution: Cold-chain validated logistics where required. Controlled drug handling protocols compliant with MHRA Schedule 2 requirements.
Testing and Documentation
Every Cannamedical Britannia product batch is accompanied by a Certificate of Analysis (COA) issued by an accredited independent laboratory. These documents are available to prescribing clinicians and dispensing pharmacies upon request and are retained on file as part of our batch traceability system.
Regulatory Compliance in the United Kingdom
Medical cannabis in the UK is classified as a Schedule 2 controlled drug under the Misuse of Drugs Regulations 2001. Import into the UK requires MHRA import authorisation. Cannamedical Britannia is progressing through the regulatory framework to achieve full UK licensing, with anticipated product availability in the UK market from 2027.
Our Formulary
Explore our strain portfolio to review the available products, chemovars and analytical documentation: View Product Formulary. For clinical partnership enquiries, visit our clinician hub.
